Zelira Therapeutics
  • HOME
  • ABOUT
    • OUR COMPANY
    • BOARD
    • ADVISORY BOARD
    • LOCATIONS
    • MEDICAL CANNABIS
      • SCIENCE
      • LEGALISED MARKETS
  • RESEARCH
    • PRODUCT PIPELINE
    • PRECLINICAL
      • PANCREATIC CANCER
      • BREAST CANCER
      • BRAIN CANCER
      • DIABETES RELATED COGNITIVE DECLINE
    • CLINICAL TRIALS
      • AUTISM
      • INSOMNIA
      • CHRONIC PAIN
  • PRODUCTS
    • Doctors
    • Pharmacists
    • Patients
  • INVESTORS
    • ASX ANNOUNCEMENTS
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
    • PRESENTATIONS & VIDEOS
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • REPORTS
    • STOCK INFORMATION
    • CORPORATE GOVERNANCE
  • MEDIA
    • VIDEOS & AUDIOS
    • ARTICLES
    • Autism Symposium
  • CONTACT
  • HOME
  • ABOUT
    •         - OUR COMPANY
    •         - BOARD
    •         - ADVISORY BOARD
    •         - LOCATIONS
    •         - MEDICAL CANNABIS
      •                 - SCIENCE
      •                 - LEGALISED MARKETS
  • RESEARCH
    •         - PRODUCT PIPELINE
    •         - PRECLINICAL
      •                 - PANCREATIC CANCER
      •                 - BREAST CANCER
      •                 - BRAIN CANCER
      •                 - DIABETES RELATED COGNITIVE DECLINE
    •         - CLINICAL TRIALS
      •                 - AUTISM
      •                 - INSOMNIA
      •                 - CHRONIC PAIN
  • PRODUCTS
    •         - Doctors
    •         - Pharmacists
    •         - Patients
  • INVESTORS
    •         - ASX ANNOUNCEMENTS
      •                 - 2021
      •                 - 2020
      •                 - 2019
      •                 - 2018
      •                 - 2017
      •                 - 2016
    •         - PRESENTATIONS & VIDEOS
      •                 - 2021
      •                 - 2020
      •                 - 2019
      •                 - 2018
      •                 - 2017
      •                 - 2016
      •                 - 2015
    •         - REPORTS
    •         - STOCK INFORMATION
    •         - CORPORATE GOVERNANCE
  • MEDIA
    •         - VIDEOS & AUDIOS
    •         - ARTICLES
    •         - Autism Symposium
  • CONTACT

Category Archives: articles-2019

CFN Media Interviews Zelda Therapeutics at New West Summit

By Zelira TherapeuticsOctober 24, 2019articles-2019, news

CFN Media Interviews Zelda Therapeutics at New West Summit

Read More

Shareholder Briefing Invitation, Perth

By Zelira TherapeuticsJune 27, 2019articles-2019

Read More

Forbes Article – Mara Gordon: Aunt Zelda’s, For Every Household

By Zelira TherapeuticsMay 30, 2019articles-2019, news

Forbes Article – Mara Gordon: Aunt Zelda’s, For Every Household

Read More

Zelda Therapeutics – Pioneering Australian Medicinal Cannabis Research

By Zelira TherapeuticsMay 14, 2019articles-2019, news

Zelda Therapeutics – Pioneering Australian Medicinal Cannabis Research

Read More

Zelda Therapeutics to outline cannabinoid-based strategy at Proactive CEO Sessions

By Zelira TherapeuticsMay 2, 2019articles-2019, news

Zelda Therapeutics to outline cannabinoid-based strategy at Proactive CEO Sessions

Read More

March 2019 Quarterly Report

By Zelira TherapeuticsApril 30, 2019articles-2019

March 2019 Quarterly Report

Read More

SUBSCRIBE

Zelira TherapeuticsFollow

Zelira Therapeutics
3 May

Zelira’s Observational Trial will be one of the largest medicinal cannabis studies ever undertaken involving a specific range of products in patients diagnosed with autism. Find out more or register your interest in the trial here https://www.emeraldclinics.com.au/clinical-trials
#ZLD #ZLDAX #ZLDAF

Twitter 1389354330185244673
Load More...

CONTACT US

    Copyright © Zelira Therapeutics. All rights reserved. | Disclaimer.